No Data
No Data
Beijing Hejing Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Beijing Hejing Biotechnology Co., Ltd.
Beijing Hotgen Biotech Co.,Ltd (688068.SH) released its semi-annual performance, with a net loss of 43.47 million yuan, a turnaround from profit to loss compared to the same period last year.
beijing hotgen biotech co.,ltd (688068.SH) disclosed its 2024 interim report, during the reporting period, the company achieved a revenue of 2.49...
Beijing Hotgen Biotech Co., Ltd. (688068.SH): Net loss of 43.4678 million yuan in the first half of the year.
Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced its semi-annual report for 2024, with revenue of 0.249 billion yuan, a year-on-year decrease of 18.96%; and a net income attributable to shareholders of the listed company of -43.4678 million yuan.
Beijing Hotgen Biotech Co., Ltd (688068.SH) has obtained multiple overseas qualifications and certifications.
Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced that the company has recently obtained three overseas qualifications and postponed one. ...
Beijing Hotgen Biotech Co., Ltd. (688068.SH): Clinical trial application for innovative drug SGC001 injection developed by affiliated company has been approved for permission.
On August 5th, Gelunhui reported that Beijing Hotgen Biotech Co., Ltd., a affiliated company of Peking Shun Jing Biomedical Technology Co., Ltd., received the issued "Drug Clinical Trial Approval Notice" from National Medical Products Administration (NMPA), notice number 2024LP01790. The clinical trial application (IND) for SGC001, an innovative drug developed by the Shun Jing Pharmaceutical Research and Development team of Professor Sun Zhiwei and the Beijing Institute of Heart, Lung, and Blood Vessel Diseases of Capital Medical University of Professor Du Jie has been approved by NMPA. SGC001 is jointly developed by Shun Jing Pharmaceutical and Professor Sun Zhiwei's research team and Professor Du Jie's team at Beijing Institute of Heart, Lung and Blood Vessel Diseases of Capital Medical University.
No Data